Natera Company Updates | Glassdoor.com.au

Company Updates

  • We are very proud to announce that the Signatera test is now commercially available for clinical use in the US and in select international countries. Signatera is the first custom-built ctDNA test for molecular treatment monitoring and molecular residual disease (MRD) ever launched for patients with solid tumors. This Wednesday we received our first test order! Learn more about Signatera at http://glassdoor.com/slink.htm?key=vM9KT.

    #Signatera #MRD #oncology #ctDNA

  • Another important study highlights Signatera's potential to change how cancer patients are managed. A JAMA Oncology study showed that our Signatera test detected colorectal cancer recurrence up to 16.5 months earlier than radiologic imaging and identified patients most likely to relapse before and after chemotherapy.

    #colorectalcancer #cancer #ctdna #oncology #signatera

    http://glassdoor.com/slink.htm?key=vMdwI

    Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer

    Question Does analysis of longitudinal data from circulating tumor DNA enable residual disease detection and risk-stratified postoperative management of stages I-III colorectal cancer? Findings In this cohort study of 125 patients and 795 plasma samples from Denmark, circulating tumor DNA was associated with relapse as were current identified risk factors, both before and after adjuvant therapy and during long-term surveillance.

  • http://glassdoor.com/slink.htm?key=vMdwK

    We are excited to announce that our Signatera test detects colorectal cancer recurrence up to 16.5 months earlier than the current standard of care.

    #colorectalcancer #cancer #ctdna #oncology #signatera

    New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier

    SAN CARLOS, Calif., May 9, 2019 /PRNewswire/ -- A new clinical study shows that Natera's Signatera™ test identified colorectal cancer recurrence up to 16.5 months earlier than radiologic imaging by detecting traces of tumor DNA in the blood after surgery. The test also identified patients most likely to relapse, both before and after chemotherapy.

  • We are pleased to announce that the FDA has granted “Breakthrough Device” designation for our Signatera test for use in the post-surgical detection and quantification of ctDNA in the blood of patients previously diagnosed with specific cancer types and in combination with certain drugs. http://glassdoor.com/slink.htm?key=vMP1Z #oncology #signatera #moleculardiagnostics #ctdna #fda

    http://glassdoor.com/slink.htm?key=vMPGa

    FDA Grants Breakthrough Device Designation to Natera's Signatera Test

    SAN CARLOS, Calif., May 6, 2019 /PRNewswire/ -- (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its Signatera™ test for use in the post-surgical detection and quantification of circulating tumor DNA (ctDNA) in the blood of patients previously diagnosed with certain types of cancer and in combination with certain drugs.

  • A new study published in the Journal of Clinical Oncology shows Signatera’s power to detect metastatic disease sooner and to predict which patients are at highest risk for recurrence, enabling earlier medical interventions. The study demonstrates that the Signatera MRD test was highly prognostic of recurrence in patients with bladder cancer and identified relapse up to 8.2 months earlier than current clinical standards with 100 percent sensitivity.

    #signatera #oncology #bladdercancer #ctdna #moleculardiagnostics

    http://glassdoor.com/slink.htm?key=vMdwj

  • The body of evidence validating Signatera continues to grow! Our blood test detects bladder cancer recurrence up to 8.2 months earlier than current standards.

    #signatera #oncology #bladdercancer #ctdna #moleculardiagnostics

    http://glassdoor.com/slink.htm?key=vMP1J

    Signatera™ Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical Standards

    SAN CARLOS, Calif., May 7, 2019 /PRNewswire/ -- (NASDAQ: NTRA) today announced the publication of a clinical validation study demonstrating that its Signatera™ molecular residual disease (MRD) test was highly prognostic of recurrence in patients with bladder cancer, and it identified recurrence up to 8.2 months earlier than current clinical standards with 100 percent sensitivity.

  • We are pleased to share the press release from the University of Leicester, one of the collaborators on the Signatera™ breast cancer trial, who along with Imperial College London and Cancer Research UK, made this study possible.

    #universityofleicester #cancerresearchuk #cancerresearch #imperialcollegelondon #liquidbiopsy #breastcancer

    http://glassdoor.com/slink.htm?key=vMP1q

    Breast cancer relapse could be found two years earlier

    Research has revealed that a new blood test is able to detect disease relapse up to two years earlier than imaging in patients with early-stage breast cancer. The research, carried out by the University of Leicester and Imperial College London and funded by Cancer Research UK, showed that the blood test was able to detect 89 per cent of all relapses, on average 8.9 months quicker than imaging.

  • We are excited to announce clinical study results published in ���������������� ������������ ����������������, showing that the Signatera (RUO) MRD assay detected molecular recurrence up to two years earlier than imaging in patients with early-stage breast cancer. This new publication validates the clinical performance of Signatera for recurrence monitoring and MRD assessment in breast cancer.

    #oncology #signateraruo #breastcancer #moleculardiagnostics #ctdna

    http://glassdoor.com/slink.htm?key=vMP1x

    New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer

    SAN CARLOS, Calif., April 16, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), Cancer Research UK, Imperial College London and the University of Leicester, today announced the publication of results of a clinical study demonstrating that the Signatera™ research-use-only (RUO) molecular residual disease (MRD) assay detected disease relapse up to two years earlier than imaging in patients with early-stage breast cancer.

  • We're excited to announce plans to commercialize a research-use-only service for whole exome sequencing of ctDNA using plasma samples from patients with cancer. #ctdna #oncology #moleculardiagnostics #wholeexome

    http://glassdoor.com/slink.htm?key=vMP1r

    Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma

    SAN CARLOS, Calif., April 10, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) Natera, a leader in cell-free DNA testing, today announced plans to commercialize a research-use-only (RUO) service for whole exome sequencing (WES) of circulating tumor DNA, using plasma samples from patients with cancer.

  • We are very pleased to announce that draft local coverage determination (LCD) has been issued by Medicare for the use of our new Prospera test to detect organ rejection in kidney transplant recipients. This represents a major reimbursement milestone on our path to commercialization. #prospera #kidney #organtransplant #medicare #moleculardiagnostics

    http://glassdoor.com/slink.htm?key=vMP1k

    Medicare Issues Draft Local Coverage Determination for Natera's New Prospera™ Kidney Transplant Rejection Test

    SAN CARLOS, Calif., March 28, 2019 /PRNewswire/ -- (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Palmetto MolDx has issued draft local coverage determination (LCD) for use of the company's new Prospera donor-derived cell-free DNA (dd-cfDNA) test to detect active rejection in kidney transplant recipients.

Work at Natera? Share Your Experiences

Natera
  • Star
  • Star
  • Star
  • Star
  • Star
 
Click to Rate
or